Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 388 matching trials from the live ClinicalTrials.gov search.
Filters: "early Alzheimer" Condition: Alzheimer's Disease Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Implementation of CAPABLE in the Michigan Medicaid Waiver

NCT03634033
View directory record Official record
Conditions
Independent Living
Interventions
MiCAP with IF (Main Study), MiCAP with IF and EF (Main Study), MiCAP with IF and Caregiver Engagement (Administrative Supplement)
Behavioral
Lead sponsor
Grand Valley State University
Other
Eligibility
21 Years and older
Enrollment
7,777 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
18
States / cities
Alpena, Michigan • Battle Creek, Michigan • Bay City, Michigan + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Effect of Physiologic Insulin Administration on Cognition

NCT06424652
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Blood draws, Hyperinsulinemic Euglycemic Clamp Technique Insulin Sensitivity test, Resting Metabolic Rate (RMR)
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
65 Years to 75 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lifestyle Enriching Activities for Research in Neuroscience Intervention Trial: LEARNit Study

NCT02726906
View directory record Official record
Conditions
Aging, Cognitive Ability, General
Interventions
Moderate-aerobic walking, Positron Emission Tomography (PET) scan, Healthy living education, Physical activity monitor
Behavioral · Radiation · Device
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Not applicable Interventional

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

NCT05637801
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Interventions
Spectris™ AD - Active, Spectris™ AD - Sham
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
68
States / cities
Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Nicotinamide as an Early Alzheimer's Disease Treatment

NCT03061474
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Nicotinamide, Placebo Comparator
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Irvine, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 13, 2026, 6:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders

NCT00911690
View directory record Official record
Conditions
Dementia, Alzheimers Disease
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
60 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 13, 2026, 6:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease

NCT00478491
View directory record Official record
Conditions
Magnetic Resonance Imaging, Alzheimer's Disease, Dementia, Adult Children, Risk
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years to 85 Years
Enrollment
390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 13, 2026, 6:41 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Interactive Physical and Cognitive Exercise System

NCT03069391
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, MCI, Aging, Mild Cognitive Impairment, Neurocognitive Disorder, Cognitive Impairment, Cognitive Change
Interventions
physical exercise alone (PES) first, cognitive exercise alone (iCE) first, interactive Physical and Cognitive Exercise (iPACES™)
Behavioral · Device
Lead sponsor
Union College, New York
Other
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Schenectady, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 13, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

Repurposing Siponimod for Alzheimer's Disease

NCT06639282
View directory record Official record
Conditions
Alzheimer Disease, Mild Alzheimer Disease, MCI With Increased Risk for Alzheimer Disease, Cognitive Impairment, Mild
Interventions
Siponimod, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
50 Years to 85 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome

NCT00965835
View directory record Official record
Conditions
Down Syndrome, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2009 · Synced Oct 13, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

NCT07236190
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
Interventions
natural product combination-1 (NPC1)
Combination Product
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Not applicable Interventional

7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD

NCT05596994
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Lighting Intervention Therapy, Sham LIT
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

NCT02859207
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
E2609
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 13, 2026, 6:41 PM EDT
Active, not recruiting Phase 3 Interventional

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

NCT04468659
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Interventions
Lecanemab, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Deep Brain Stimulation with LIFUP for Mild Cognitive Impairment and Mild Alzheimer's Disease

NCT03347084
View directory record Official record
Conditions
Brain Imaging, Mild Cognitive Impairment, Alzheimer Disease, Deep Brain Stimulation
Interventions
Excitation, Inhibition
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
55 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 13, 2026, 6:41 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO

NCT02835716
View directory record Official record
Conditions
Alzheimer Disease
Interventions
roflumilast, ustekinumab
Drug · Biological
Lead sponsor
Millennium Magnetic Technologies, LLC
Industry
Eligibility
50 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Westport, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 13, 2016 · Synced Oct 13, 2026, 6:41 PM EDT
Terminated Phase 3 Interventional Results available

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

NCT02484547
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab (BIIB037), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Memory and Insulin in Early Alzheimer's Disease

NCT00581867
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Insulin Aspart, Placebo
Drug
Lead sponsor
Jeff Burns, MD
Other
Eligibility
60 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Senolytic Therapy to Modulate Progression of Alzheimer's Disease

NCT04063124
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Dasatinib + Quercetin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 13, 2026, 6:41 PM EDT
Active, not recruiting Not applicable Interventional

Neurophysiological Benefits of Live Music for Early Alzheimer's Patients and Their Caregivers

NCT06940687
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment, Peer-bonded Caregiver, Caregiver
Interventions
Pre-recorded Music Session, Live Music Session
Behavioral
Lead sponsor
Yale University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease

NCT02958930
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease, Late Onset
Interventions
MemorEM 1000
Device
Lead sponsor
NeuroEM Therapeutics, Inc.
Industry
Eligibility
63 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 13, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

NCT03935568
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PU-AD, Placebo
Drug
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 13, 2026, 6:41 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β

NCT06470061
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
Interventions
Resveratrol, Quercetin, and Curcumin (RQC), Curcumin
Drug
Lead sponsor
Zaparackas and Knepper LTD
Other
Eligibility
50 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 13, 2026, 6:41 PM EDT
Recruiting Phase 1 Interventional

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

NCT06297590
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3954068, Placebo, Flortaucipir F18
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Maitland, Florida • The Villages, Florida • Decatur, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 13, 2026, 6:41 PM EDT